US Bio Company Initiates Large-Scale Share Buyback, Executives Cash Out

United Therapeutics Corporation (NASDAQ: UTHR) announced on March 9 that its board of directors has authorized a share repurchase program of up to $2.0 billion over the next 12 months, roughly KRW 2.6 trillion. Of that amount, $1.5 billion (about KRW 2.0 trillion) will be deployed immediately under an accelerated share repurchase agreement with Citibank.

Subsequently, on March 20 and March 23, the company’s CEO and CFO each exercised stock options under pre-arranged Rule 10b5-1 trading plans, then sold an equivalent number of common shares in the open market, realizing gains in the tens of millions of Korean won and modestly reducing their direct holdings.

The stock recently jumped more than 10% in a single day late in March—trading near its 52-week high—after United Therapeutics reported that Tyvaso, its inhaled therapy for pulmonary arterial hypertension, met the primary endpoint in the Phase 3 TETON-1 trial in patients with idiopathic pulmonary fibrosis (source: Investing.com).

Looking ahead, the company plans to submit an additional new drug application for a new indication of Tyvaso by this summer, and in the second half of 2026 it intends to file a New Drug Application with the U.S. Food and Drug Administration for ralinepag, its oral treatment for pulmonary arterial hypertension, signaling further pipeline expansion (source: Investing.com).

Headquartered in Maryland, United Therapeutics is a biotechnology firm specializing in treatments for rare pulmonary diseases—including pulmonary arterial hypertension—alongside the development of artificial organs and xenotransplantation technologies (source: Wikipedia). Increasing investor interest in high-priced orphan-disease therapies and transplant-related innovations has driven notable volatility in UTHR’s share price, tied to clinical milestones, regulatory timelines, and its large-scale share repurchase strategy (source: Ainvest.com).